New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2012
08:36 EDTRGRXRegeneRx completes license agreement for development of RegeneRx products
RegeneRx announced that it has entered into a licensing agreement with Lee's Pharmaceutical Limited for the license to Lee's of RegeneRx's Thymosin Beta 4-based products, including the company's RGN-259, RGN-352 and RGN-137 product candidates, in China and Taiwan. Lee's previously paid RegeneRx $200,000 upon signing of a term sheet and will pay RegeneRx an additional $200,000 with the completion of this license agreement. The terms of the deal include aggregate potential milestone payments of up to $3.6M and royalties ranging from low double digit to high single digit royalties on commercial sales. RegeneRx also has the right to exclusively license any improvements made by Lee's to RegeneRx's products outside of the licensed territory.
News For RGRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2015
11:41 EDTRGRXRegeneRx receives Australian patent acceptance for TB4 peptide fragment
RegeneRx announced that the Australian government has issued a Notice of Acceptance for a patent for a key peptide fragment of Thymosin beta 4. The patent claims are directed to the composition of matter and methods of use, including inhibiting tissue damage caused by ultraviolet radiation and promoting neurite outgrowth and neuron survival, among others. The patent expiry is expected to be 2029.
July 17, 2015
11:01 EDTRGRXRegeneRx's GtreeBNT receives Korean approval to conduct clinical trial
Subscribe for More Information
July 14, 2015
12:48 EDTRGRXUSPTO issues notice of allowance for patent covering administration of TB4
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use